Go Pro
→ How Elon’s Empire Ends (and how to profit) (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$20.33
+1.3%		$18.26
$9.56
▼
$21.17
$6.49B1.212.20 million shs1.61 million shs
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
$159.47
-2.2%		$166.36
$72.65
▼
$200.00
$6.42B-1.23192,943 shs134,885 shs
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$100.00
+0.4%		$100.80
$49.67
▼
$111.86
$6.53B-0.061.09 million shs447,650 shs
Perrigo Company plc stock logo
PRGO
Perrigo
$14.28
+1.9%		$13.37
$9.23
▼
$22.65
$1.98B0.693.10 million shs1.44 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
-0.35%+1.31%+13.52%+17.03%+93.35%
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-4.03%-3.81%+4.01%+11.15%+121.74%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
+0.12%-0.07%-1.22%-9.32%+93.01%
Perrigo Company plc stock logo
PRGO
Perrigo
-4.80%-4.58%-2.25%+27.64%-37.58%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$20.33
+1.3%		$18.26
$9.56
▼
$21.17
$6.49B1.212.20 million shs1.61 million shs
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
$159.47
-2.2%		$166.36
$72.65
▼
$200.00
$6.42B-1.23192,943 shs134,885 shs
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$100.00
+0.4%		$100.80
$49.67
▼
$111.86
$6.53B-0.061.09 million shs447,650 shs
Perrigo Company plc stock logo
PRGO
Perrigo
$14.28
+1.9%		$13.37
$9.23
▼
$22.65
$1.98B0.693.10 million shs1.44 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
-0.35%+1.31%+13.52%+17.03%+93.35%
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-4.03%-3.81%+4.01%+11.15%+121.74%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
+0.12%-0.07%-1.22%-9.32%+93.01%
Perrigo Company plc stock logo
PRGO
Perrigo
-4.80%-4.58%-2.25%+27.64%-37.58%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
2.90
Moderate Buy$21.004.29% Upside
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
2.64
Moderate Buy$218.7334.66% Upside
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
2.29
Hold$108.118.14% Upside
Perrigo Company plc stock logo
PRGO
Perrigo
2.00
Hold$19.3334.85% Upside

Current Analyst Ratings Breakdown

Latest PRGO, BLTE, LNTH, and AMRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/1/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/25/2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C) ➝ Hold (C+)
9/23/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$27.00
9/17/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$16.00 ➝ $20.00
9/10/2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C+) ➝ Hold (C)
9/9/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$220.00 ➝ $234.00
9/9/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
9/9/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$23.00
9/9/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$23.00
9/8/2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$245.00
9/7/2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$3.02B2.13$1.56 per share12.90($0.23) per share-87.55
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/AN/AN/AN/A$20.54 per shareN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.54B4.23$6.41 per share15.59$16.43 per share6.08
Perrigo Company plc stock logo
PRGO
Perrigo
$4.25B0.47$5.14 per share2.79$21.33 per share0.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$72.06M$0.4941.1018.652.365.05%-584.46%7.78%N/A
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-$77.61M-$2.73N/A178.49N/AN/A-11.84%-11.62%11/9/2026 (Estimated)
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$233.56M$4.1424.1518.31N/A17.69%28.10%14.35%11/5/2026 (Estimated)
Perrigo Company plc stock logo
PRGO
Perrigo
-$1.43B-$12.51N/A6.081.69-41.85%11.25%4.08%11/4/2026 (Estimated)

Latest PRGO, BLTE, LNTH, and AMRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2026Q2 2026
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
-$0.73-$0.54+$0.19-$0.70N/AN/A
8/6/2026Q2 2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.30$1.55+$0.25$1.11$363.23 million$388.18 million
8/5/2026Q2 2026
Perrigo Company plc stock logo
PRGO
Perrigo
$0.3880$0.50+$0.1120$0.53$1.02 billion$1.02 billion
7/30/2026Q2 2026
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
$0.24$0.30+$0.06$0.18N/A$796.20 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
N/AN/AN/AN/AN/A
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/AN/AN/AN/AN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
N/AN/AN/AN/AN/A
Perrigo Company plc stock logo
PRGO
Perrigo
$1.168.09%+5.21%N/A 23 Years

Latest PRGO, BLTE, LNTH, and AMRX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/30/2026
Perrigo Company plc stock logo
PRGO
Perrigo
quarterly$0.297.98%8/28/20268/28/20269/15/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
77.65
2.20
1.44
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
N/A
33.56
33.56
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
0.43
3.06
2.89
Perrigo Company plc stock logo
PRGO
Perrigo
1.31
2.32
1.32

Institutional Ownership

CompanyInstitutional Ownership
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
31.82%
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
0.53%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
99.06%
Perrigo Company plc stock logo
PRGO
Perrigo
95.91%

Insider Ownership

CompanyInsider Ownership
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
17.30%
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
13.29%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
1.70%
Perrigo Company plc stock logo
PRGO
Perrigo
0.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amneal Pharmaceuticals, Inc. stock logo
AMRX
Amneal Pharmaceuticals
8,500319.35 million264.11 millionOptionable
Belite Bio, Inc. Sponsored ADR stock logo
BLTE
Belite Bio
4140.27 million34.92 millionNot Optionable
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
1,19365.27 million64.16 millionOptionable
Perrigo Company plc stock logo
PRGO
Perrigo
8,100138.77 million138.21 millionOptionable

Recent News About These Companies

Perrigo (NYSE:PRGO) Cut to Buy at Wall Street Zen
September 27, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31053707
Perrigo (NYSE:PRGO) Stock Moved Down to Buy by Wall Street Zen
September 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-perrigo-nyse-prgo-stock-moved-down-to-buy-by-wall-street-zen-2026-09-27/
Perrigo (PRGO) Moves 6.1% Higher: Will This Strength Last?
September 25, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2995628/perrigo-prgo-moves-6-1-higher-will-this-strength-last?cid=cs-stocknewsapi-ft-fundamental_analysis|daily_price_change_5%-2995628
Squarepoint Ops LLC Cuts Position in Perrigo Company plc $PRGO
September 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-squarepoint-ops-llc-cuts-position-in-perrigo-company-plc-prgo-2026-09-25/
Perrigo (NYSE:PRGO) Stock Price Up 5.9% - Should You Buy?
September 24, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-perrigo-nyse-prgo-stock-price-up-59-should-you-buy-2026-09-24/
Perrigo Company plc (NYSE:PRGO) Given Average Rating of "Hold" by Brokerages
September 23, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31041028
Contrasting Pfizer (NYSE:PFE) & Perrigo (NYSE:PRGO)
September 23, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31040588
Perrigo (NYSE:PRGO) Upgraded at Wall Street Zen
September 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-perrigo-nyse-prgo-upgraded-at-wall-street-zen-2026-09-19/
Perrigo Company plc (NYSE:PRGO) Receives Consensus Rating of "Hold" from Analysts
September 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-perrigo-company-plc-nyse-prgo-receives-consensus-rating-of-hold-from-analysts-2026-09-18/
Perrigo (NYSE:PRGO) Share Price Passes Above Two Hundred Day Moving Average - Here's What Happened
September 12, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-perrigo-nyse-prgo-share-price-passes-above-two-hundred-day-moving-average-heres-what-happened-2026-09-12/
Perrigo (PRGO) Up 13.8% Since Last Earnings Report: Can It Continue?
September 4, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2985356/perrigo-prgo-up-13-8-since-last-earnings-report-can-it-continue?cid=cs-stocknewsapi-ft-realtime_blog-2985356
Perrigo to Attend the Barclays Global Consumer Conference
August 27, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/perrigo-to-attend-the-barclays-global-consumer-conference-302860909.html
PRGO or NEOG: Which Is the Better Value Stock Right Now?
August 26, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2980435/prgo-or-neog-which-is-the-better-value-stock-right-now?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_3-2980435
Should Value Investors Buy Perrigo (PRGO) Stock?
August 26, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2980271/should-value-investors-buy-perrigo-prgo-stock?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_2-2980271
Perrigo Company plc
August 24, 2026  |  money.usnews.comhttps://money.usnews.com/investing/stocks/prgo-perrigo-company-plc/vitals
This Under-the-Radar Healthcare Stock Yields Nearly 8.5%. Here's Whether That Income Is Too Good to Be True.
August 22, 2026  |  fool.comhttps://www.fool.com/investing/2026/08/22/this-under-the-radar-healthcare-stock-yields-nearl/?source=marketbeat&utm_source=marketbeat&utm_medium=feed&utm_campaign=article&referring_guid=699ea541-1d38-4111-8d93-b9b5f57d6237
Perrigo Co. PLC stock underperforms Tuesday when compared to competitors despite daily gains
August 19, 2026  |  marketwatch.comhttps://www.marketwatch.com/data-news/perrigo-co-plc-stock-underperforms-tuesday-when-compared-to-competitors-despite-daily-gains-7572901d-4a755786cc62
Perrigo Earnings Call Balances Pressure and Progress
August 16, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/perrigo-earnings-call-balances-pressure-and-progress?utm_source=marketbeat.com&utm_medium=referral
Perrigo: The Rebound Is Just Getting Started
August 13, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4935695-perrigo-q2-rebound-is-just-getting-started?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
Perrigo (PRGO) Q2 2026 Earnings Call Transcript
August 12, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/perrigo-prgo-q2-2026-earnings-135901756.html
Perrigo Co. PLC stock outperforms competitors on strong trading day
August 11, 2026  |  marketwatch.comhttps://www.marketwatch.com/data-news/perrigo-co-plc-stock-outperforms-competitors-on-strong-trading-day-0cae28b9-5e6cb459712e

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amneal Pharmaceuticals stock logo

Amneal Pharmaceuticals NASDAQ:AMRX

$20.33 +0.26 (+1.31%)
Closing price 03:59 PM Eastern
Extended Trading
$20.30 -0.03 (-0.14%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Belite Bio stock logo

Belite Bio NASDAQ:BLTE

$159.46 -3.52 (-2.16%)
Closing price 03:59 PM Eastern
Extended Trading
$159.46 0.00 (0.00%)
As of 04:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Lantheus stock logo

Lantheus NASDAQ:LNTH

$100.00 +0.35 (+0.36%)
Closing price 03:59 PM Eastern
Extended Trading
$99.90 -0.11 (-0.11%)
As of 04:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Perrigo stock logo

Perrigo NYSE:PRGO

$14.28 +0.26 (+1.85%)
Closing price 03:59 PM Eastern
Extended Trading
$14.26 -0.02 (-0.18%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas